Literature DB >> 11816795

Lewy body pathology in Alzheimer's disease.

P T Kotzbauer1, J Q Trojanowsk, V M Lee.   

Abstract

Lewy bodies, the characteristic pathological lesion of substantia nigra neurons in Parkinson's disease (PD), are frequently observed to accompany the amyloid plaque and neurofibrillary tangle pathology of Alzheimer's disease (AD). However the typical anatomic distribution of Lewy bodies in AD is distinct from PD. The most common site of occurrence is the amygdala, where Lewy bodies are observed in approximately 60% of both sporadic and familial AD. Other common sites of occurrence include the periamygdaloid and entorhinal cortex, while neocortical and brainstem areas develop Lewy bodies in a lower percentage of cases. In contrast, dementia with Lewy bodies (DLB), defined by widespread neocortical and brainstem Lewy bodies but frequently accompanied by variable levels of AD-type pathology, represents the other end of a spectrum of pathology associated with dementia. The observation of Lewy bodies in familial AD cases suggests that like neurofibrillary tangles, the formation of Lewy bodies can be induced by the pathological state caused by Abeta-amyloid overproduction. The role of Lewy body formation in the dysfunction and degeneration of neurons remains unclear. The protein alpha-synuclein appears to be an important structural component of Lewy bodies, an observation spurred by the discovery of point mutations in the alpha-synuclein gene linked to rare cases of autosomal dominant PD. Further investigation of alpha-synuclein and its relationship to pathological conditions promoting Lewy body formation in AD, PD, and DLB may yield further insight into pathogenesis of these diseases.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11816795     DOI: 10.1385/jmn:17:2:225

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   3.444


  80 in total

1.  Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease.

Authors:  H I Hurtig; J Q Trojanowski; J Galvin; D Ewbank; M L Schmidt; V M Lee; C M Clark; G Glosser; M B Stern; S M Gollomp; S E Arnold
Journal:  Neurology       Date:  2000-05-23       Impact factor: 9.910

Review 2.  The role of mitochondrial dysfunction and neuronal nitric oxide in animal models of neurodegenerative diseases.

Authors:  J B Schulz; R T Matthews; T Klockgether; J Dichgans; M F Beal
Journal:  Mol Cell Biochem       Date:  1997-09       Impact factor: 3.396

3.  Both familial Parkinson's disease mutations accelerate alpha-synuclein aggregation.

Authors:  L Narhi; S J Wood; S Steavenson; Y Jiang; G M Wu; D Anafi; S A Kaufman; F Martin; K Sitney; P Denis; J C Louis; J Wypych; A L Biere; M Citron
Journal:  J Biol Chem       Date:  1999-04-02       Impact factor: 5.157

4.  Clinical and neuropathological correlates of dementia with Lewy bodies.

Authors:  E Gómez-Tortosa; M C Irizarry; T Gómez-Isla; B T Hyman
Journal:  Ann N Y Acad Sci       Date:  2000       Impact factor: 5.691

5.  Enhanced vulnerability to oxidative stress by alpha-synuclein mutations and C-terminal truncation.

Authors:  S Kanda; J F Bishop; M A Eglitis; Y Yang; M M Mouradian
Journal:  Neuroscience       Date:  2000       Impact factor: 3.590

6.  Widespread occurrence of alpha-synuclein/NACP-immunoreactive neuronal inclusions in juvenile and adult-onset Hallervorden-Spatz disease with Lewy bodies.

Authors:  K Wakabayashi; M Yoshimoto; T Fukushima; R Koide; Y Horikawa; T Morita; H Takahashi
Journal:  Neuropathol Appl Neurobiol       Date:  1999-10       Impact factor: 8.090

7.  alpha-Synuclein shares physical and functional homology with 14-3-3 proteins.

Authors:  N Ostrerova; L Petrucelli; M Farrer; N Mehta; P Choi; J Hardy; B Wolozin
Journal:  J Neurosci       Date:  1999-07-15       Impact factor: 6.167

8.  Membrane association and protein conformation of alpha-synuclein in intact neurons. Effect of Parkinson's disease-linked mutations.

Authors:  P J McLean; H Kawamata; S Ribich; B T Hyman
Journal:  J Biol Chem       Date:  2000-03-24       Impact factor: 5.157

9.  Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease.

Authors:  K Uéda; H Fukushima; E Masliah; Y Xia; A Iwai; M Yoshimoto; D A Otero; J Kondo; Y Ihara; T Saitoh
Journal:  Proc Natl Acad Sci U S A       Date:  1993-12-01       Impact factor: 11.205

10.  Neuropathological diagnoses in elderly patients in Oslo: Alzheimer's disease, Lewy body disease, vascular lesions.

Authors:  P G Ince; F K McArthur; E Bjertness; A Torvik; J M Candy; J A Edwardson
Journal:  Dementia       Date:  1995 May-Jun
View more
  52 in total

1.  Biomarkers in Alzheimer's disease drug development.

Authors:  Kaj Blennow
Journal:  Nat Med       Date:  2010-09-21       Impact factor: 53.440

2.  Modulation of GABAergic transmission by muscarinic receptors in the entorhinal cortex of juvenile rats.

Authors:  Zhaoyang Xiao; Pan-Yue Deng; Chuanxiu Yang; Saobo Lei
Journal:  J Neurophysiol       Date:  2009-06-03       Impact factor: 2.714

3.  Activation of group II metabotropic glutamate receptors inhibits glutamatergic transmission in the rat entorhinal cortex via reduction of glutamate release probability.

Authors:  Shouping Wang; Xiaotong Chen; Lalitha Kurada; Zitong Huang; Saobo Lei
Journal:  Cereb Cortex       Date:  2011-06-15       Impact factor: 5.357

Review 4.  Does the oxysterol 27-hydroxycholesterol underlie Alzheimer's disease-Parkinson's disease overlap?

Authors:  Gurdeep Marwarha; Othman Ghribi
Journal:  Exp Gerontol       Date:  2014-09-28       Impact factor: 4.032

5.  Abnormal Sleep Behaviours Across the Spectrum of Alzheimer's Disease Severity: Influence of APOE Genotypes and Lewy Bodies.

Authors:  Ka Yi G Koo; Tom A Schweizer; Corinne E Fischer; David G Munoz
Journal:  Curr Alzheimer Res       Date:  2019       Impact factor: 3.498

6.  Differentiating Alzheimer disease-associated aggregates with small molecules.

Authors:  Nicolette S Honson; Ronald L Johnson; Wenwei Huang; James Inglese; Christopher P Austin; Jeff Kuret
Journal:  Neurobiol Dis       Date:  2007-07-28       Impact factor: 5.996

7.  Serotonergic modulation of Neural activities in the entorhinal cortex.

Authors:  Saobo Lei
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2012-12-26

8.  Is it time for biomarker-based diagnostic criteria for prodromal Alzheimer's disease?

Authors:  Kaj Blennow; Henrik Zetterberg
Journal:  Alzheimers Res Ther       Date:  2010-04-30       Impact factor: 6.982

9.  A Caenorhabditis elegans model system for amylopathy study.

Authors:  Zhibing Duan; Federico Sesti
Journal:  J Vis Exp       Date:  2013-05-17       Impact factor: 1.355

10.  The 1.1-A resolution crystal structure of DJ-1, the protein mutated in autosomal recessive early onset Parkinson's disease.

Authors:  Mark A Wilson; Jennifer L Collins; Yaacov Hod; Dagmar Ringe; Gregory A Petsko
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-10       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.